View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+
Protocol-ID: 969 V1.2 (Mini), STUDY NIVEAU - NIVO240/RITU375/GEMC1000/OXAL100, DLBCL, C2+Study protocol, available to authorized participants only.
Indication(s)
- NHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive; ICD-10 C84.6
- NHL, B-Cell Type, Diffuse Large Cell (CD20+); ICD-10 C83.3
- NHL, B-Cell Type, Follicular grade IIIb; ICD-10 C82.-, C82.7, C82.9
- NHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell Lymphoma; ICD-10 C85.2
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 30.05.2024